These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 6251513)

  • 1. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney.
    Schwertschlag U; Stahl T; Hackenthal E
    Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of prostacyclin by 9-hydroxyprostaglandin dehydrogenase in human platelets. Formation of a potent inhibitor of platelet aggregation and enzyme purification.
    Wong PY; Lee WH; Chao PH; Reiss RF; McGiff JC
    J Biol Chem; 1980 Oct; 255(19):9021-4. PubMed ID: 6997309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
    Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1.
    Oyekan AO; Botting JH
    Prostaglandins; 1987 Sep; 34(3):359-66. PubMed ID: 3324168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet aggregation by 6-keto-PGE1; lack of an effect on cyclic GMP levels.
    Pontecorvo EG; Myers CB; Lippton HL; Kadowitz PJ
    Prostaglandins Med; 1981 May; 6(5):473-83. PubMed ID: 6267636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.
    Wilsoncroft PS; Lofts FJ; Griffiths RJ; Moore PK
    J Pharm Pharmacol; 1985 Feb; 37(2):139-41. PubMed ID: 2858551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the prostacyclin products, 6-keto prostaglandin E1 and 6-keto prostaglandin F1 alpha, on bone resorption in vitro.
    Neuman SD; Raisz LG
    Prostaglandins Leukot Med; 1984 Jul; 15(1):103-8. PubMed ID: 6382342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
    Fitscha P; Kaliman J; Sinzinger H
    Am J Hematol; 1985 May; 19(1):13-9. PubMed ID: 3885723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue.
    Jackson EK; Herzer WA; Zimmerman JB; Branch RA; Oates JA; Gerkens JF
    J Pharmacol Exp Ther; 1981 Jan; 216(1):24-7. PubMed ID: 7005428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-keto PGE1: a possible metabolite of prostacyclin having platelet antiaggregatory effects.
    Quilley CP; McGiff JC; Lee WH; Sun FF; Wong PY
    Hypertension; 1980; 2(4):524-8. PubMed ID: 6995292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-keto-PGE1 exhibits more potent bronchodilatory activity in the cat than its precursor, PGI2.
    Spannhake EW; Levin JL; Hyman AL; Kadowitz PJ
    Prostaglandins; 1981 Feb; 21(2):267-75. PubMed ID: 7012934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of some pharmacological actions of prostaglandin E1, 6-oxo-PGE1 and PGI2.
    Adaikan PG; Tai NY; Lau LC; Karim SM; Kottegoda SR
    Prostaglandins; 1984 Apr; 27(4):505-16. PubMed ID: 6203140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypotensive response to prostacyclin and 6-keto-PGE1 following hepatectomy in the rat.
    Van Dam J; Stinger RB; Penhos JC; Ramwell PW; Kot PA
    Proc Soc Exp Biol Med; 1984 Sep; 176(4):438-42. PubMed ID: 6379654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Keto-prostaglandin E1 is a potent coronary vasodilator and stimulates a vagal reflex in dogs.
    Panzenbeck MJ; Hintze TH; Kaley G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):814-9. PubMed ID: 3075239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin-related renin release from rabbit renal cortical slices.
    Spokas EG; Wong PY; McGiff JC
    Hypertension; 1982; 4(3 Pt 2):96-100. PubMed ID: 7040243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination from the circulation of cats of 6-keto-prostaglandin E1 compared with prostaglandins E2 and I2.
    Förstermann U; Neufang B
    J Pharm Pharmacol; 1983 Nov; 35(11):724-8. PubMed ID: 6139453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Keto-prostaglandin E1: its formation by platelets from prostacyclin and resistance to pulmonary degradation.
    Berry CN; Hoult JR
    Pharmacology; 1983; 26(6):324-30. PubMed ID: 6348806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.